Cargando…
Detection of methylated BCAT1 and IKZF1 after curative‐intent treatment as a prognostic indicator for colorectal cancer recurrence
BACKGROUND: The risk of recurrence after completion of curative‐intent treatment of colorectal cancer (CRC) is hard to predict. Post‐treatment assaying for circulating tumor DNA (ctDNA) is an encouraging approach for stratifying patients for therapy, but the prognostic value of this approach is less...
Autores principales: | Pedersen, Susanne K., Symonds, Erin L., Roy, Amitesh C., Cornthwaite, Kathryn J., LaPointe, Lawrence C., Young, Graeme P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883422/ https://www.ncbi.nlm.nih.gov/pubmed/35822405 http://dx.doi.org/10.1002/cam4.5008 |
Ejemplares similares
-
Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia
por: Pedersen, Susanne K., et al.
Publicado: (2015) -
Methylation and Gene Expression of BCAT1 and IKZF1 in Colorectal Cancer Tissues
por: Jedi, Maher, et al.
Publicado: (2018) -
A Blood Test for Methylated BCAT1 and IKZF1 vs. a Fecal Immunochemical Test for Detection of Colorectal Neoplasia
por: Symonds, Erin L, et al.
Publicado: (2016) -
Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1
por: Symonds, Erin L., et al.
Publicado: (2022) -
Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer
por: Young, Graeme P., et al.
Publicado: (2021)